Thrivent Financial for Lutherans Acquires 6,045 Shares of Gilead Sciences, Inc. $GILD

Thrivent Financial for Lutherans grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the fourth quarter, Holdings Channel reports. The firm owned 979,033 shares of the biopharmaceutical company’s stock after buying an additional 6,045 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Gilead Sciences were worth $120,173,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Triton Wealth Management PLLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth $183,000. Arbejdsmarkedets Tillaegspension bought a new stake in shares of Gilead Sciences in the 4th quarter worth $23,918,000. Avantax Planning Partners Inc. increased its holdings in shares of Gilead Sciences by 10.0% in the 4th quarter. Avantax Planning Partners Inc. now owns 3,632 shares of the biopharmaceutical company’s stock worth $446,000 after purchasing an additional 329 shares in the last quarter. Simmons Bank increased its holdings in shares of Gilead Sciences by 2.8% in the 4th quarter. Simmons Bank now owns 38,201 shares of the biopharmaceutical company’s stock worth $4,689,000 after purchasing an additional 1,052 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Gilead Sciences by 259.1% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 4,011 shares of the biopharmaceutical company’s stock worth $492,000 after purchasing an additional 2,894 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings raised Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Citigroup lifted their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Cantor Fitzgerald reduced their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Wolfe Research lifted their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Daiwa Securities Group raised their price target on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $157.04.

Gilead Sciences Stock Performance

GILD stock opened at $132.06 on Friday. The company has a market cap of $163.96 billion, a P/E ratio of 17.99 and a beta of 0.31. Gilead Sciences, Inc. has a 1 year low of $97.86 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock’s fifty day moving average price is $138.14 and its 200-day moving average price is $133.25.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock worth $9,238,250 in the last ninety days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.